Minerva Neurosciences, Inc (NERV): Price and Financial Metrics

Minerva Neurosciences, Inc (NERV): $2.50

0.04 (-1.57%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add NERV to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#219 of 360

in industry

NERV Price/Volume Stats

Current price $2.50 52-week high $13.49
Prev. close $2.54 52-week low $2.02
Day low $2.45 Volume 15,100
Day high $2.57 Avg. volume 111,627
50-day MA $4.88 Dividend yield N/A
200-day MA $6.76 Market Cap 17.48M

NERV Stock Price Chart Interactive Chart >


Minerva Neurosciences, Inc (NERV) Company Bio


Minerva Neurosciences, Inc. focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company was founded in 2007 and is based in Waltham, Massachusetts.


NERV Latest News Stream


Event/Time News Detail
Loading, please wait...

NERV Latest Social Stream


Loading social stream, please wait...

View Full NERV Social Stream

Latest NERV News From Around the Web

Below are the latest news stories about MINERVA NEUROSCIENCES INC that investors may wish to consider to help them evaluate NERV as an investment opportunity.

Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates

BURLINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the third quarter ended September 30, 2023. The Company continues to work with the U.S. Food and Drug Administration (FDA) during its review of its New Drug Application (NDA) for roluperidone for the treatment of negati

Yahoo | November 7, 2023

12 Best Performing Biotech Stocks in 2023

In this piece, we will take a look at the 12 best performing biotechnology stocks in 2023. If you want to skip our introduction to the biotechnology industry and some top players, then check out 5 Best Performing Biotech Stocks in 2023. Biotechnology is one of the hottest industries these days and one that has […]

Yahoo | October 20, 2023

Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates

BURLINGTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the second quarter ended June 30, 2023. “In the second quarter, we completed an equity financing of $20.0 million, further strengthening our cash position. This investment from Boehringer Ingelheim and Federated Hermes

Yahoo | August 1, 2023

Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market

BURLINGTON, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it has agreed to sell an aggregate of 1,425,000 shares of its common stock at a purchase price of $10 per share and pre-funded warrants to purchase an aggregate of 575,575 shares of its common stock at a purchase price of $9.99 per pre-funded warrant, to B

Yahoo | June 28, 2023

Here's Why Minerva Neurosciences (NERV) Is a Great 'Buy the Bottom' Stock Now

Minerva Neurosciences (NERV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Yahoo | June 9, 2023

Read More 'NERV' Stories Here

NERV Price Returns

1-mo -10.39%
3-mo N/A
6-mo -55.60%
1-year 9.65%
3-year -87.55%
5-year -95.73%
YTD -59.35%
2023 286.79%
2022 -75.19%
2021 -65.77%
2020 -67.09%
2019 5.49%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!